S
Steven L. Shafer
Researcher at Stanford University
Publications - 311
Citations - 17406
Steven L. Shafer is an academic researcher from Stanford University. The author has contributed to research in topics: Pharmacokinetics & Remifentanil. The author has an hindex of 61, co-authored 284 publications receiving 16420 citations. Previous affiliations of Steven L. Shafer include Veterans Health Administration & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
The Influence of Method of Administration and Covariates on the Pharmacokinetics of Propofol in Adult Volunteers
Thomas W. Schnider,Charles F. Minto,Pedro L. Gambús,Corina Andresen,David B. Goodale,Steven L. Shafer,Elizabeth J. Youngs +6 more
TL;DR: It is demonstrated that method of administration (bolus vs. infusion), but not EDTA, influences the pharmacokinetics of propofol, and within the clinically relevant range, the kinetics of Propofol during infusions are linear regarding infusion rate.
Journal ArticleDOI
Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development
Charles F. Minto,Thomas W. Schnider,Talmage D. Egan,Elizabeth J. Youngs,Harry J. M. Lemmens,Pedro L. Gambús,Valerie Billard,John F. Hoke,Katherine H. P. Moore,David J. Hermann,Keith T. Muir,Jaap W. Mandema,Steven L. Shafer +12 more
TL;DR: The aim of this study was to determine the influence of age and gender on the pharmacokinetics and pharmacodyn of fentanyl, alfent anil, and sufentanil.
Journal ArticleDOI
The Influence of Age on Propofol Pharmacodynamics
Thomas W. Schnider,Charles F. Minto,Steven L. Shafer,Pedro L. Gambús,Corina Andresen,David B. Goodale,Elizabeth J. Youngs +6 more
TL;DR: Semilinear canonical correlation defined a new measure of prop ofol effect on the EEG, the canonical univariate parameter for propofol, which is faster than previously reported and indicates Elderly patients are more sensitive to the hypnotic and EEG effects of propofl than are younger persons.
Journal ArticleDOI
Pharmacokinetics and Pharmacodynamics of Remifentanil: II. Model Application
TL;DR: Age and LBM are significant demographic factors that must be considered when determining a dosage regimen for remifentanil, and simulations suggest that the time required for a decrease in effect site concentrations will be more variable in the elderly.
Journal ArticleDOI
The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers.
Talmage D. Egan,Harry J. M. Lemmens,Pierre Fiset,David J. Hermann,Keith T. Muir,Donald R. Stanski,Steven L. Shafer +6 more
TL;DR: The computer simulation revealed the strikingly unique pharmacokinetic profile of remifentanil compared to that of the currently available fentanyl family of opioids.